Establishment Labs Holdings Inc. (ESTA) – What Are Researchers Thinking About This Stock?

Posted by Stanley Muller on Oct 23rd, 2026

Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $98.56.

ESTA has been the topic of a number of recent analyst reports. Stifel Nicolaus set a $85.00 price target on shares of Establishment Labs and gave the company a “buy” rating in a report on Wednesday, October 14th. JPMorgan Chase & Co. boosted their price objective on shares of Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Canaccord Genuity Group set a $105.00 target price on shares of Establishment Labs in a research report on Thursday, August 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, September 21st. Finally, Mizuho lifted their price target on shares of Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th.

Check Out Our Latest Analysis on ESTA

Institutional Trading of Establishment Labs

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Establishment Labs during the 2nd quarter worth $135,752,000. William Blair Investment Management LLC purchased a new stake in Establishment Labs in the second quarter valued at about $61,273,000. Bank of America Corp DE purchased a new stake in Establishment Labs in the second quarter valued at about $52,176,000. Rice Hall James & Associates LLC purchased a new stake in Establishment Labs in the second quarter valued at about $48,134,000. Finally, Nantahala Capital Management LLC acquired a new stake in Establishment Labs in the second quarter worth about $28,817,572. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Stock Performance

Establishment Labs stock opened at $63.52 on Friday. The business has a fifty day moving average of $68.19 and a two-hundred day moving average of $74.59. The company has a debt-to-equity ratio of 12.11, a quick ratio of 2.52 and a current ratio of 3.84. Establishment Labs has a twelve month low of $47.00 and a twelve month high of $97.59.

Establishment Labs (NASDAQ:ESTA – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. The company had revenue of $67.54 million for the quarter, compared to the consensus estimate of $65.79 million. During the same period last year, the business posted ($0.57) EPS. The firm’s revenue was up 31.7% compared to the same quarter last year. On average, research analysts predict that Establishment Labs will post -1.08 EPS for the current fiscal year.

Establishment Labs Company Profile

(Get Free Report)

Establishment Labs Holdings Inc is a medical technology company focused on women’s health and the breast aesthetics market. The company develops, manufactures and commercializes breast implants and related technologies designed for breast augmentation, reconstruction and revision procedures.

Its product portfolio includes the Motiva line of breast implants, which incorporates the company’s proprietary implant materials, surface technologies and design features. Establishment Labs also offers Motiva Flora tissue expanders for use in breast reconstruction and has developed Mia Femtech, a minimally invasive breast enhancement procedure intended to provide a less invasive alternative to traditional augmentation techniques.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves physicians, hospitals and patients in international markets.